177Lu-HTK03170 in mCRPC With PSMA Positive Disease
Status:
Not yet recruiting
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
This study will determine the safe initial injected activity of the radioligand therapy
177Lu-HTK03170 for the measurement of dosimetry and initiation of treatment in subjects with
PSMA-positive, metastatic castrate resistant prostate cancer, (mCRPC). Subjects will receive
treatment which will be escalated between cycles and personalized based on dosimetry
calculations and imaging. In addition, antitumour activity will be measured by radiographic
response, and further assessments of the treatment will be measured by CT imaging,
ctDNA/ctRNA, PSA, PSMA PET/CT, and quality of life questionnaires. Subjects will be followed
for 2 years or until they have progression and are switched to another systemic treatment.